Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

Neratinib augments the lethality of [regorafenib + sildenafil].

Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Hancock JF, Poklepovic A, Dent P.

J Cell Physiol. 2018 Sep 10. doi: 10.1002/jcp.27276. [Epub ahead of print]

PMID:
30203445
2.

Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.

Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Sep 5:1-12. doi: 10.1080/15384047.2018.1507665. [Epub ahead of print]

PMID:
30183517
3.

Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.

Booth L, Roberts JL, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Aug 24:1-13. doi: 10.1080/15384047.2018.1507258. [Epub ahead of print]

PMID:
30142009
4.

Increased cardiac sympathetic nerve activity in ovine heart failure is reduced by lesion of the area postrema, but not lamina terminalis.

Abukar Y, Ramchandra R, Hood SG, McKinley MJ, Booth LC, Yao ST, May CN.

Basic Res Cardiol. 2018 Aug 3;113(5):35. doi: 10.1007/s00395-018-0695-9.

PMID:
30076468
5.

The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.

Booth L, Roberts J, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Jul 19:1-11. doi: 10.1080/15384047.2018.1472189. [Epub ahead of print]

PMID:
30024813
6.

Age and gender stratified normative values for the International Prostate Symptom Score for adults aged 60 years and over.

Booth L, Skelton DA, Hagen S, Booth J.

Neurourol Urodyn. 2018 Jun 21. doi: 10.1002/nau.23735. [Epub ahead of print]

PMID:
29926963
7.

Valproate augments Niraparib killing of tumor cells.

Booth L, Roberts JL, Rais R, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Jun 20:1-12. doi: 10.1080/15384047.2018.1472190. [Epub ahead of print]

PMID:
29923797
8.

Teaching Spiritual Care Within Nursing Education: A Holistic Approach.

Booth L, Kaylor S.

Holist Nurs Pract. 2018 Jul/Aug;32(4):177-181. doi: 10.1097/HNP.0000000000000271.

PMID:
29894372
9.

Cognitive Training and Transcranial Direct Current Stimulation for Mild Cognitive Impairment in Parkinson's Disease: A Randomized Controlled Trial.

Lawrence BJ, Gasson N, Johnson AR, Booth L, Loftus AM.

Parkinsons Dis. 2018 Mar 26;2018:4318475. doi: 10.1155/2018/4318475. eCollection 2018.

10.

Integrating Optimal Screening, Intervention, and Referral for Postpartum Depression in Adolescents.

Booth L, Wedgeworth M, Turner A.

Nurs Clin North Am. 2018 Jun;53(2):157-168. doi: 10.1016/j.cnur.2018.01.003. Review.

PMID:
29779510
11.

Effects of Clonidine on the Cardiovascular, Renal and Inflammatory Responses to Experimental Bacteremia.

Calzavacca P, Booth LC, Lankadeva YR, Bailey SR, Burrell LM, Bailey M, Bellomo R, May CN.

Shock. 2018 Feb 27. doi: 10.1097/SHK.0000000000001134. [Epub ahead of print]

PMID:
29489737
12.

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.

Booth L, Roberts JL, Rais R, Kirkwood J, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Oncotarget. 2017 Dec 26;9(5):6062-6074. doi: 10.18632/oncotarget.23681. eCollection 2018 Jan 19.

13.

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells.

Booth L, Roberts JL, Kirkwood J, Poklepovic A, Dent P.

Adv Cancer Res. 2018;137:1-15. doi: 10.1016/bs.acr.2017.11.004. Epub 2018 Jan 3.

PMID:
29405973
14.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.

Booth L, Roberts JL, Samuel P, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Jun 3;19(6):525-533. doi: 10.1080/15384047.2018.1436024. Epub 2018 Mar 6.

PMID:
29405820
15.

TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition.

Lima S, Takabe K, Newton J, Saurabh K, Young MM, Leopoldino AM, Hait NC, Roberts JL, Wang HG, Dent P, Milstien S, Booth L, Spiegel S.

Autophagy. 2018;14(6):942-957. doi: 10.1080/15548627.2018.1429875. Epub 2018 Mar 11.

PMID:
29368980
16.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.

Booth L, Roberts JL, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Mar 4;19(3):239-247. doi: 10.1080/15384047.2018.1423927. Epub 2018 Jan 22.

PMID:
29333953
17.

Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy.

Kirtane AR, Abouzid O, Minahan D, Bensel T, Hill AL, Selinger C, Bershteyn A, Craig M, Mo SS, Mazdiyasni H, Cleveland C, Rogner J, Lee YL, Booth L, Javid F, Wu SJ, Grant T, Bellinger AM, Nikolic B, Hayward A, Wood L, Eckhoff PA, Nowak MA, Langer R, Traverso G.

Nat Commun. 2018 Jan 9;9(1):2. doi: 10.1038/s41467-017-02294-6.

18.

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species.

Roberts JL, Poklepovic A, Booth L.

Oncotarget. 2017 Aug 2;8(59):99451-99469. doi: 10.18632/oncotarget.19807. eCollection 2017 Nov 21.

19.

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.

Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dent P.

Cancer Biol Ther. 2018 Feb 1;19(2):132-137. doi: 10.1080/15384047.2017.1394556. Epub 2017 Dec 8.

20.

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P.

Oncotarget. 2017 Oct 9;8(52):90262-90277. doi: 10.18632/oncotarget.21660. eCollection 2017 Oct 27.

21.

HDAC inhibitors enhance the immunotherapy response of melanoma cells.

Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P.

Oncotarget. 2017 May 17;8(47):83155-83170. doi: 10.18632/oncotarget.17950. eCollection 2017 Oct 10.

22.

Tracking and responding to an outbreak of tuberculosis using MIRU-VNTR genotyping and whole genome sequencing as epidemiological tools.

Black AT, Hamblion EL, Buttivant H, Anderson SR, Stone M, Casali N, Drobniewski F, Nwoguh F, Marshall BG, Booth L.

J Public Health (Oxf). 2018 Jun 1;40(2):e66-e73. doi: 10.1093/pubmed/fdx075.

PMID:
29106587
23.

Defining optimal permeant characteristics for ultrasound-mediated gastrointestinal delivery.

Schoellhammer CM, Chen Y, Cleveland C, Minahan D, Bensel T, Park JY, Saxton S, Lee YL, Booth L, Langer R, Traverso G.

J Control Release. 2017 Dec 28;268:113-119. doi: 10.1016/j.jconrel.2017.10.023. Epub 2017 Oct 16.

PMID:
29051063
24.

Recovery of brodifacoum in vomitus following induction of emesis in dogs that had ingested rodenticide bait.

Parton KH, Willson EK, Collett MG, Booth LH.

N Z Vet J. 2018 Jan;66(1):41-43. doi: 10.1080/00480169.2017.1379915. Epub 2017 Oct 11.

PMID:
28920541
25.

[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells.

Booth L, Roberts JL, Poklepovic A, Dent P.

Cancer Biol Ther. 2017 Sep 2;18(9):705-714. doi: 10.1080/15384047.2017.1362511.

26.

Triggerable tough hydrogels for gastric resident dosage forms.

Liu J, Pang Y, Zhang S, Cleveland C, Yin X, Booth L, Lin J, Lucy Lee YA, Mazdiyasni H, Saxton S, Kirtane AR, Erlach TV, Rogner J, Langer R, Traverso G.

Nat Commun. 2017 Jul 25;8(1):124. doi: 10.1038/s41467-017-00144-z.

27.

Student radiographers' attitudes towards the older patient - A longitudinal study.

Booth L, Kada S, Satinovic M, Phillips P, Miller PK.

Radiography (Lond). 2017 Aug;23(3):229-234. doi: 10.1016/j.radi.2017.03.014. Epub 2017 Apr 18.

PMID:
28687291
28.

Prolonged energy harvesting for ingestible devices.

Nadeau P, El-Damak D, Glettig D, Kong YL, Mo S, Cleveland C, Booth L, Roxhed N, Langer R, Chandrakasan AP, Traverso G.

Nat Biomed Eng. 2017;1. pii: 0022. doi: 10.1038/s41551-016-0022. Epub 2017 Feb 6.

29.

Wireless Power Transfer to Millimeter-Sized Gastrointestinal Electronics Validated in a Swine Model.

Abid A, O'Brien JM, Bensel T, Cleveland C, Booth L, Smith BR, Langer R, Traverso G.

Sci Rep. 2017 Apr 27;7:46745. doi: 10.1038/srep46745.

30.

Obesity, heuristic reasoning and the organisation of communicative embarrassment in diagnostic radiography.

Miller PK, Woods AL, Sloane C, Booth L.

Radiography (Lond). 2017 May;23(2):130-134. doi: 10.1016/j.radi.2016.12.002. Epub 2017 Jan 6.

PMID:
28390544
31.

Leadership and the everyday practice of Consultant Radiographers in the UK: Transformational ideals and the generation of self-efficacy.

Booth L, Henwood S, Miller PK.

Radiography (Lond). 2017 May;23(2):125-129. doi: 10.1016/j.radi.2016.12.003. Epub 2017 Jan 5.

PMID:
28390543
32.

Dementia and clinical interaction in frontline radiography: Mapping the practical experiences of junior clinicians in the UK.

Miller PK, Booth L, Spacey A.

Dementia (London). 2017 Jan 1:1471301217700742. doi: 10.1177/1471301217700742. [Epub ahead of print]

PMID:
28361579
33.

Catheter-Based Renal Denervation Exacerbates Blood Pressure Fall During Hemorrhage.

Singh RR, Sajeesh V, Booth LC, McArdle Z, May CN, Head GA, Moritz KM, Schlaich MP, Denton KM.

J Am Coll Cardiol. 2017 Feb 28;69(8):951-964. doi: 10.1016/j.jacc.2016.12.014.

34.

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.

Booth L, Roberts JL, Sander C, Lee J, Kirkwood JM, Poklepovic A, Dent P.

Oncotarget. 2017 Mar 7;8(10):16367-16386. doi: 10.18632/oncotarget.14829.

35.

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].

Booth L, Roberts JL, Poklepovic A, Dent P.

Oncotarget. 2017 Feb 21;8(8):13464-13475. doi: 10.18632/oncotarget.14562.

36.

AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded Proteins.

Booth L, Roberts JL, Ecroyd H, Reid SP, Proniuk S, Zukiwski A, Jacob A, Damonte E, Tuñón MJ, Dent P.

J Clin Cell Immunol. 2016 Oct;7(5). pii: 454. Epub 2016 Sep 16. No abstract available.

37.

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide.

Booth L, Roberts JL, Poklepovic A, Gordon S, Dent P.

Oncotarget. 2017 Jan 3;8(1):1449-1468. doi: 10.18632/oncotarget.13640.

38.

Oral, ultra-long-lasting drug delivery: Application toward malaria elimination goals.

Bellinger AM, Jafari M, Grant TM, Zhang S, Slater HC, Wenger EA, Mo S, Lee YL, Mazdiyasni H, Kogan L, Barman R, Cleveland C, Booth L, Bensel T, Minahan D, Hurowitz HM, Tai T, Daily J, Nikolic B, Wood L, Eckhoff PA, Langer R, Traverso G.

Sci Transl Med. 2016 Nov 16;8(365):365ra157.

39.

Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.

Booth L, Albers T, Roberts JL, Tavallai M, Poklepovic A, Lebedyeva IO, Dent P.

Oncotarget. 2016 Jun 28;7(26):40398-40417. doi: 10.18632/oncotarget.9752.

40.

Circumferential optical coherence tomography angiography imaging of the swine esophagus using a micromotor balloon catheter.

Lee HC, Ahsen OO, Liang K, Wang Z, Cleveland C, Booth L, Potsaid B, Jayaraman V, Cable AE, Mashimo H, Langer R, Traverso G, Fujimoto JG.

Biomed Opt Express. 2016 Jul 5;7(8):2927-42. doi: 10.1364/BOE.7.002927. eCollection 2016 Aug 1.

41.

Compassion: a universal language.

Booth L.

Contemp Nurse. 2016 Apr-Jun;52(2-3):366-8. doi: 10.1080/10376178.2016.1221325. Epub 2016 Aug 18.

PMID:
27536804
42.

Repurposing Tecfidera for cancer.

Booth L, Malkin M, Dent P.

Aging (Albany NY). 2016 Jul;8(7):1289-90. doi: 10.18632/aging.101001. No abstract available.

43.

Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.

Tavallai M, Booth L, Roberts JL, Poklepovic A, Dent P.

Front Oncol. 2016 Jun 13;6:142. doi: 10.3389/fonc.2016.00142. eCollection 2016.

44.

The Aging Epigenome.

Booth LN, Brunet A.

Mol Cell. 2016 Jun 2;62(5):728-44. doi: 10.1016/j.molcel.2016.05.013. Review.

45.

Suitability of the Depression, Anxiety, and Stress Scale in Parkinson's Disease.

Johnson AR, Lawrence BJ, Corti EJ, Booth L, Gasson N, Thomas MG, Loftus AM, Bucks RS.

J Parkinsons Dis. 2016 May 27;6(3):609-16. doi: 10.3233/JPD-160842.

PMID:
27258699
46.

Renal Nitric Oxide Deficiency and Chronic Kidney Disease in Young Sheep Born with a Solitary Functioning Kidney.

Singh RR, Easton LK, Booth LC, Schlaich MP, Head GA, Moritz KM, Denton KM.

Sci Rep. 2016 May 26;6:26777. doi: 10.1038/srep26777.

47.

Phase I study of pemetrexed with sorafenib in advanced solid tumors.

Poklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE Jr, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent P.

Oncotarget. 2016 Jul 5;7(27):42625-42638. doi: 10.18632/oncotarget.9434.

48.

AR-12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication.

Booth L, Roberts JL, Ecroyd H, Tritsch SR, Bavari S, Reid SP, Proniuk S, Zukiwski A, Jacob A, Sepúlveda CS, Giovannoni F, García CC, Damonte E, González-Gallego J, Tuñón MJ, Dent P.

J Cell Physiol. 2016 Oct;231(10):2286-302. doi: 10.1002/jcp.25431. Epub 2016 Jun 6.

PMID:
27187154
49.

[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.

Booth L, Roberts JL, Tavallai M, Chuckalovcak J, Stringer DK, Koromilas AE, Boone DL, McGuire WP, Poklepovic A, Dent P.

Oncotarget. 2016 Apr 26;7(17):23608-32. doi: 10.18632/oncotarget.8281.

50.

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.

Tavallai M, Booth L, Roberts JL, McGuire WP, Poklepovic A, Dent P.

Oncotarget. 2016 Apr 5;7(14):17290-300. doi: 10.18632/oncotarget.8039.

Supplemental Content

Support Center